# Autologous T-cells Genetically Engineered to Express Receptors Reactive Against KRAS Mutations in Conjunction With a Vaccine Directed Against These Antigens in Participants With Metastatic Cancer

> **NCT06253520** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **National Cancer Institute (NCI)** · enrollment: 210 (estimated)

## Conditions studied

- Metastatic Solid Cancers
- Colorectal Cancer
- Breast Cancer
- Non-Small Cell Lung Cancer
- Gastrointestinal Cancer
- Ovarian Cancer
- Genitourinary Cancer

## Interventions

- **DRUG:** Aldesleukin
- **DRUG:** Fludarabine
- **DRUG:** Cyclophosphamide
- **BIOLOGICAL:** KRAS TCR-Transduced PBL
- **BIOLOGICAL:** GRT-C903/GRT-R904

## Key facts

- **NCT ID:** NCT06253520
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2024-05-16
- **Primary completion:** 2029-02-20
- **Final completion:** 2029-02-20
- **Target enrollment:** 210 (ESTIMATED)
- **Last updated:** 2026-05-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06253520

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06253520, "Autologous T-cells Genetically Engineered to Express Receptors Reactive Against KRAS Mutations in Conjunction With a Vaccine Directed Against These Antigens in Participants With Metastatic Cancer". Retrieved via AI Analytics 2026-08-15 from https://api.ai-analytics.org/clinical/NCT06253520. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*